This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $554,188 to The Trustees of the University of Pennsylvania to develop and advance silver telluride nanoparticle contrast agents for improved breast cancer screening via dual-energy mammography. The key products and services to be delivered under this 5-year award include: Adapting the nanoparticle synthesis process to be scalable using microfluidic chip technology, characterizing the scaled-up nanoparticles, and testing them in breast cancer models. The team will also transfer the manufacturing process to a contract research organization (CRO) for GMP production, conduct excretion and safety studies in two species, and perform virtual clinical trials to inform future clinical trial design. The aim is to generate a lead nanoparticle formulation ready to enter clinical trials, with the goal of enhancing breast cancer detection and reducing mortality from the disease, particularly in women with dense breasts.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $554.2k | 3/24/25 |